ArticleFrontiers in immunology2019
Tools for Assessing the Protective Efficacy of TB Vaccines in Humans:
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Development and application of the direct mycobacterial growth inhibition assay: a systematic review.Frontiers in immunology · 2024Pooled it
- Safety and immunogenicity of ChAdOx1 85A prime followed by MVA85A boost compared with BCG revaccination among Ugandan adolescents who received BCG at birth: a randomised, open-label trial.The Lancet. Infectious diseases · 2024Trial
- Functional in-vitro evaluation of the non-specific effects of BCG vaccination in a randomised controlled clinical study.Scientific reports · 2022Trial
- Induction of Functional Specific Antibodies, IgG-Secreting Plasmablasts and Memory B Cells Following BCG Vaccination.Frontiers in immunology · 2021Trial
- Antibodies in tuberculosis: functional capacity as key determinant.Infection and immunity · 2026Review
- The BCGMethodsX · 2025Article
- MetE: a promising protective antigen for tuberculosis vaccine development.Frontiers in immunology · 2025Article
- The mark of success: The role of vaccine-induced skin scar formation for BCG and smallpox vaccine-associated clinical benefits.Seminars in immunopathology · 2024Review
- A modified mycobacterial growth inhibition assay for the functional assessment of vaccine-mediated immunity.NPJ vaccines · 2024Article
- Shared challenges to the control of complex intracellular neglected pathogens.Frontiers in public health · 2024Review
- A dose escalation study to evaluate the safety of an aerosol BCG infection in previously BCG-vaccinated healthy human UK adults.Frontiers in immunology · 2024Article
- Design and Characterization of a Multistage Peptide-Based Vaccine Platform to TargetBioconjugate chemistry · 2023Article
- Evaluation ofFrontiers in cellular and infection microbiology · 2023Article
- Factors associated with the humoral response after three doses of COVID-19 vaccination in kidney transplant recipients.Frontiers in immunology · 2023Article
- Control ofFrontiers in immunology · 2023Article
- A novel multistage antigens ERA005f confer protection againstFrontiers in immunology · 2023Article
- Accelerating research and development of new vaccines against tuberculosis: a global roadmap.The Lancet. Infectious diseases · 2022Review
- High-dose Mycobacterium tuberculosis aerosol challenge cannot overcome BCG-induced protection in Chinese origin cynomolgus macaques; implications of natural resistance for vaccine evaluation.Scientific reports · 2021Article
- Review
- A non-human primate in vitro functional assay for the early evaluation of TB vaccine candidates.NPJ vaccines · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
Tuberculosis (TB) remains a leading global cause of morbidity and mortality and an effective new vaccine is urgently needed. A major barrier to the rational development of novel TB vaccines is the lack of a validated immune correlate or biomarker of protection. Mycobacterial Growth Inhibition Assays (MGIAs) provide an unbiased measure of ability to control mycobacterial growth
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.